摘要
目的探讨沙格列汀对2型糖尿病患者血糖、血压的影响及安全性。方法将我院收治的2型糖尿病患者84例纳入本组研究,根据数字表法随机分为沙格列汀组和对照组,每组42例。2组患者均给予常规治疗和护理干预,对照组患者在常规治疗的基础上给予阿卡波糖,3次/d,50mg/次,连续治疗3个月。沙格列汀组患者在常规治疗的基础上给予沙格列汀,1次/d,5mg/次,连续治疗3个月。1对比2组患者治疗前后的空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbA1c);2对比2组患者治疗前后体质指数、肌酐、尿素氮水平以及收缩压、舒张压、24h平均收缩压、24h平均舒张压的差异。结果 2组患者在治疗过程中均未出现低血糖和低血压病例以及药物不良反应,2组患者治疗后的FBG、2hBG、HbA1c明显低于治疗前(均P<0.05);沙格列汀组患者治疗后收缩压、24h平均收缩压明显低于治疗前(均P<0.05);经Spearman秩相关分析显示,沙格列汀组患者血压下降与FBG、2hBG、HbA1c的降低无明显相关性(P值均>0.05)。结论沙格列汀能明显降低2型糖尿病患者的血糖和血压水平,在控制血糖和血压的同时能防止血糖和血压过度降低,对患者体质量和肾脏功能无明显影响,安全性较高,但远期效果和安全性还需要进一步证实。
Objective To discuss the influence and safety of the saxagliptin on blood glucose and blood pres- sure of patients with type 2 diabetes. Methods Eighty-four cases of patients diagnosed as type 2 diabetes were col- lected and randomly divided into saxagliptin group and control group for study, forty-two cases in each. All pa- tients were given conventional treatment and nursing intervention. The patients in the control group were given acarbose on the basis of routine treatment, 3 times/d, 50 rag/time, continuous treatment for 3 months, while those in the saxagliptin group received saxagliptin on the basis of routine treatment, 1 time/d, 5 mg/time, contin- uous treatment for 3 months. （~）The fasting blood glucose（FBG）, 2-hour postprandial blood glucose（2 h BG） and hemoglobin Alc（HbA1 c） were compared between the two groups before and after treatment. QThe differences of body mass index, creatinine, urea nitrogen level, systolic pressure, diastolic pressure,24 h average systolic pres- sure and 24 h average diastolic pressure were also compared between the two groups before and after treat- ment. Results All patients in the two groups have no hypoglycemia, hypotension and drug adverse reaction during the treatment. The FBG, 2 h BG and HbAlc in the two groups were significantly lower than those before treat- ment （ P 〈0.05）. The systolic pressure and 24 h average systolic pressure in the saxagliptin group were signifi- cantly lower than those before treatment （ P 〈0.05）. There was no significant correlation between the decrease of blood pressure and the decrease of FBG, 2 h BG and HbA1 c in the saxagliptin group by Spearman analysis （all P 〉0.05）. Conclusion Saxagliptin, with high safety and no significant effect on body mass and kidney function, can significantly reduce blood glucose and blood pressure of patients with type 2 diabetes, and can also prevent blood glucose and blood pressure from excessive decreasing at the same time,, but the long-term effect and safety still need fur
出处
《山西医药杂志》
CAS
2016年第6期636-639,共4页
Shanxi Medical Journal
关键词
糖尿病
2型
血压
沙格列汀
二肽基肽酶-4抑制剂
Diabetes mellitus type 2
Blood pressure
Saxagliptin
Dipeptidyl peptidase-4 inhibitor
